정밀의료 기반 암 진단･치료법 개발(K-MASTER) 사업단
The Cancer Precision Medicine Diagnosis and Treatment (K-MASTER) Enterprise
0
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
“Precision” trials, using reasonably integrated biomarker targets and molecularly selective anticancer agents, have become a major concern for both patients and their physicians. As next-generation sequencing, which is a parallel analysis method, becomes quicker, easier, and more accurate, precision medicine-based approaches are becoming more generalized in determining treatments for cancer patients. However, it is not applicable to all cancer patients because of current high prices, limited reimbursement coverage, low prevalence of driver genetic mutations, and lack of treatable drugs. To solve these problems, the Republic of Korea has been operating the Cancer Precision Medicine Diagnosis and Treatment (K-MASTER) Enterprise since its establishment in June 2017. The aim of the project was to conduct large-scale genomic analyses, appropriate matching targeted clinical trials, and data management, which incorporates genomic and clinical information. In this review, we introduce the goals and composition of this project and describe the progress of the project to date.
Abstract
“Precision” trials, using reasonably integrated biomarker targets and molecularly selective anticancer agents, have become a major concern for both patients and their physicians. As next-generation sequencing, which is a parallel analysis method, becomes quicker, easier, and more accurate, precision medicine-based approaches are becoming more generalized in determining treatments for cancer patients. However, it is not applicable to all cancer patients because of current high prices, limited reimbursement coverage, low prevalence of driver genetic mutations, and lack of treatable drugs. To solve these problems, the Republic of Korea has been operating the Cancer Precision Medicine Diagnosis and Treatment (K-MASTER) Enterprise since its establishment in June 2017. The aim of the project was to conduct large-scale genomic analyses, appropriate matching targeted clinical trials, and data management, which incorporates genomic and clinical information. In this review, we introduce the goals and composition of this project and describe the progress of the project to date.
참고문헌 (14)
- Collins FS, "A new initiative on precision medicine", N Engl J Med, 372, pp.793~795 (2015)
- The National Academies Collection, "Toward precision medicine:building a knowledge network for biomedical research and a new taxonomy of disease" (2011), National Academies Press
- Schwaederle M, "Precision oncology : the UC San Diego Moores Cancer Center PREDICT experience", Mol Cancer Ther, 15, pp.743~752 (2016)
- Carr TH, "Defining actionable mutations for oncology therapeutic development", Nat Rev Cancer, 16, pp.319~329 (2016)
- Pao W, "EGF receptor gene mutations are common in lung cancers from"never smokers"and are associated with sensitivity of tumors to gefitinib and erlotinib", Proc Natl Acad Sci U S A, 101, pp.13306~13311 (2004)
- Kazandjian D, "FDA approval summary : crizotinib for the treatment of metastatic non-small cell lung cancer with anaplastic lymphoma kinase rearrangements", Oncologist, 19, pp.e5~e11 (2014)
- Chapman PB, "Improved survival with vemurafenib in melanoma with BRAF V600E mutation", N Engl J Med, 364, pp.2507~2516 (2011)
- Hauschild A, "Dabrafenib in BRAF-mutated metastatic melanoma : a multicentre, openlabel, phase 3 randomised controlled trial", Lancet, 380, pp.358~365 (2012)
- Kummar S, "Application of molecular profiling in clinical trials for advanced metastatic cancers", J Natl Cancer Inst, 107 (2015)
- Catenacci DV, "Next-generation clinical trials : novel strategies to address the challenge of tumor molecular heterogeneity", Mol Oncol, 9, pp.967~996 (2015)
- Morash M, "The role of next-generation sequencing in precision medicine : a review of outcomes in oncology", J Pers Med, 8, pp.30~ (2018)
- Heitzer E, "Circulating tumor DNA as a liquid biopsy for cancer", Clin Chem, 61, pp.112~123 (2015)
- Coyne GO, "Defining precision : the precision medicine initiative trials NCI-MPACT and NCIMATCH", Curr Probl Cancer, 41, pp.182~193 (2017)
- Okamoto W, "Integration of clinical information and molecular biology profile-endeavor of SCRUM-Japan-", Nihon Rinsho, 74, pp.1812~1817 (2016)